Dengue virus models based on mice as experimental hosts

Future Virology

Volumn 10, Issue 7, 2015, Pages 835-844

  Amorim, Jaime Henrique ^a   Bizerra, Raíza ^a   Dos Santos Alves, Rúbens Prince ^a   Nascimento Fabris, Denicar Lina ^a   De Souza Ferreira, Luís Carlos ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

dengue virus; mouse models; vaccine

Indexed keywords

ANTIVIRUS AGENT; DENGUE VACCINE;

DENGUE; DENGUE VIRUS; EXPERIMENTAL HOST; EXPERIMENTAL INFECTION; EXPERIMENTAL MODEL; HOST RANGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS STRAIN;

ANIMALIA; DENGUE VIRUS; MUS;

EID: 84938675916     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.15.48     Document Type: Review

References (102)

1. Guzman MG, Halstead SB, Artsob H et al. Dengue: a continuing global threat. Nat. Rev. Microbiol. 8(12), S7-S16 (2010).
2. WHO. Dengue and severe dengue. www. who. int/mediacentre/factsheets/fs117/ en
3. Bhatt S, Gething PW, Brady OJ et al. The global distribution and burden of dengue. Nature 496(7446), 504-507 (2013).
4. Sabin AB. Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1(1), 30-50 (1952).
5. Sabin AB, Schlesinger RW. Production of immunity to dengue with virus modified by propagation in mice. Science 101(2634), 640-642 (1945).
6. Halstead SB. Dengue haemorrhagic fever-a public health problem and a field for research. Bull. World Health Organ. 58(1), 1-21 (1980).
7. Henchal EA, Putnak JR. The dengue viruses. Clin. Microbiol. Rev. 3(4), 376-396 (1990).
8. Hammon WM, Rudnick A, Sather GE. Viruses associated with epidemic hemorrhagic fevers of the Philippines and Thailand. Science 131(3407), 1102-1103 (1960).
9. Cassetti MC, Durbin A, Harris E et al. Report of an NIAID workshop on dengue animal models. Vaccine 28(26), 4229-4234 (2010).
10. Wengler G, Gross HJ. Studies on virusspecific nucleic acids synthesized in vertebrate and mosquito cells infected with flaviviruses. Virology 89(2), 423-437 (1978).
11. Markoff L. 5'-and 3'-noncoding regions in flavivirus RNA. Adv. Virus Res. 59, 177-228 (2003).
12. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 5(7), 518-528 (2007).
13. Avirutnan P, Malasit P, Seliger B, Bhakdi S, Husmann M. Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. J. Immunol. 161(11), 6338-6346 (1998).
14. Cabrera-Hernandez A, Thepparit C, Suksanpaisan L, Smith DR. Dengue virus entry into liver (HepG2) cells is independent of hsp90 and hsp70. J. Med. Virol. 79(4), 386-392 (2007).
15. Chu JJH, Leong PWH, Ng ML. Analysis of the endocytic pathway mediating the infectious entry of mosquito-borne flavivirus West Nile into Aedes albopictus mosquito (C6/36) cells. Virology 349(2), 463-475 (2006).
16. Edgil D, Diamond MS, Holden KL, Paranjape SM, Harris E. Translation efficiency determines differences in cellular infection among dengue virus type 2 strains. Virology 317(2), 275-290 (2003).
17. Gromowski GD, Barrett ADT. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366(2), 349-360 (2007).
18. Halstead SB, Tom MC, Elm JLJ. In vitro virulence marker: growth of dengue-2 virus in human leukocyte suspension cultures. Infect. Immun. 31(1), 102-106 (1981).
19. Huang K-J, Yang Y-C, Lin Y-S et al. The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J. Immunol. 176(5), 2825-2832 (2006).
20. Littaua R, Kurane I, Ennis FA. Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J. Immunol. 144(8), 3183-3186 (1990).
21. Van der Schaar HM, Rust MJ, Waarts B-L et al. Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. J. Virol. 81(21), 12019-12028 (2007).
22. Chen Y, Maguire T, Hileman RE et al. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3(8), 866-871 (1997).
23. Ren J, Ding T, Zhang W, Song J, Ma W. Does Japanese encephalitis virus share the same cellular receptor with other mosquitoborne flaviviruses on the C6/36 mosquito cells? Virol. J. 4, 83 (2007).
24. Lozach P-Y, Burleigh L, Staropoli I et al. Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DCSIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals. J. Biol. Chem. 280(25), 23698-23708 (2005).
25. Chu JJ-H, Ng M-L. Interaction of West Nile virus with alpha v beta 3 integrin mediates virus entry into cells. J. Biol. Chem. 279(52), 54533-54541 (2004).
26. Miller JL, de Wet BJM, deWet BJM et al. The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog. 4(2), e17 (2008).
27. Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 75(16), 7769-7773 (2001).
28. Van der Schaar HM, Wilschut JC, Smit JM. Role of antibodies in controlling dengue virus infection. Immunobiology 214(7), 613-29 (2009).
29. Lawson D, Arensburger P, Atkinson P et al. VectorBase: a home for invertebrate vectors of human pathogens. Nucleic Acids Res. 35(Database issue), D503-D505 (2007). in developing experimental infection models.
30. Nene V, Wortman JR, Lawson D et al. Genome sequence of Aedes aegypti a major arbovirus vector. Science 316(5832), 1718-1723 (2007).
31. Sessions OM, Barrows NJ, Souza-Neto JA et al. Discovery of insect and human dengue virus host factors. Nature 458(7241), 1047-1050 (2009).
32. Aguirre S, Maestre AM, Pagni S et al. DENV inhibits TypeI IFN production in infected cells by cleaving human STING. PLoS Pathog. 8(10), e1002934 (2012).
33. Yu C-Y, Chang T-H, Liang J-J et al. Dengue virus targets the adaptor protein MITA to subvert host innate immunity. PLoS Pathog. 8(6), e1002780 (2012).
34. Althouse BM, Durbin AP, Hanley KA, Halstead SB, Weaver SC, Cummings DAT. Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysis. Virology 452-453, 237-246 (2014).
35. Halstead SB, Shotwell H, Casals J. Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection. J. Infect. Dis. 128(1), 7-14 (1973).
36. Scherer WF, Russell PK, Rosen L, Casals J, Dickerman RW. Experimental infection of chimpanzees with dengue viruses. Am. J. Trop. Med. Hyg. 27(3), 590-599 (1978).
37. Atrasheuskaya A, Petzelbauer P, Fredeking TM, Ignatyev G. Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol. Med. Microbiol. 35(1), 33-42 (2003).
38. Bray M, Men R, Tokimatsu I, Lai CJ. Genetic determinants responsible for acquisition of dengue type 2 virus mouse neurovirulence. J. Virol. 72(2), 1647-1651 (1998).
39. Chen H-C, Hofman FM, Kung JT, Lin Y-D. Wu-Hsieh BA. Both virus and tumor necrosis factor alpha are critical for endothelium damage in a mouse model of dengue virus-induced hemorrhage. J. Virol. 81(11), 5518-5526 (2007).
40. Wu-Hsieh BA, Yen Y-T, Chen H-C. Dengue hemorrhage in a mouse model. Ann. NY Acad. Sci. 1171, E42-E47 (2009).
41. Yauch LE, Shresta S. Dengue virus vaccine development. Adv. Virus Res. 88, 315-372 (2014).
42. Van den Broek MF, Müller U, Huang S, Aguet M, Zinkernagel RM. Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J. Virol. 69(8), 4792-4796 (1995).
43. Edelman R, Wasserman SS, Bodison SA et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am. J. Trop. Med. Hyg. 69(6), 48-60 (2003).
44. Blaney JEJ, Matro JM, Murphy BR, Whitehead SS. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J. Virol. 79(9), 5516-5528 (2005).
45. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 5(7), 518-528 (2007).
46. Sabchareon A, Wallace D, Sirivichayakul C et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380(9853), 1559-1567 (2012).
47. Guy B, Almond J, Lang J. Dengue vaccine prospects: a step forward. Lancet 377(9763), 381-382 (2011).
48. Villar L, Dayan GH, Arredondo-García JL et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N. Engl. J. Med. 372(2), 141103114505002 (2014).
49. An J, Kimura-Kuroda J, Hirabayashi Y, Yasui K. Development of a novel mouse model for dengue virus infection. Virology 263(1), 70-77 (1999).
50. Bente DA, Melkus MW, Garcia JV, Rico-Hesse R. Dengue fever in humanized NOD/SCID mice. J. Virol. 79(21), 13797-13799 (2005).
51. Lin YL, Liao CL, Chen LK et al. Study of dengue virus infection in SCID mice engrafted with human K562 cells. J. Virol. 72(12), 9729-9737 (1998).
52. Tan GK, Ng JKW, Trasti SL, Schul W, Yip G, Alonso S. A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl. Trop. Dis. 4(4), e672 (2010).
53. Wu SJ, Hayes CG, Dubois DR et al. Evaluation of the severe combined immunodeficient (SCID) mouse as an animal model for dengue viral infection. Am. J. Trop. Med. Hyg. 52(5), 468-476 (1995).
54. Johnson AJ, Roehrig JT. New mouse model for dengue virus vaccine testing. J. Virol. 73(1), 783-786 (1999).
55. Balsitis SJ, Williams KL, Lachica R et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 6(2), e1000790 (2010).
56. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol. 80(20), 10208-10217 (2006).
57. Zellweger RM, Prestwood TR, Shresta S. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7(2), 128-139 (2010).
58. Christofferson RC, McCracken MK, Johnson A-M, Chisenhall DM, Mores CN. Development of a transmission model for dengue virus. Virol. J. 10, 127 (2013).
59. Züst R, Toh Y-X, Valdés I et al. Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines. J. Virol. 88(13), 7276-7285 (2014).
60. Akkina R. New generation humanized mice for virus research: comparative aspects and future prospects. Virology 435(1), 14-28 (2013).
61. Legrand N, Ploss A, Balling R et al. Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe 6(1), 5-9 (2009).
62. Berges BK, Rowan MR. The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment. Retrovirology 8 65 (2011).
63. Shultz LD, Saito Y, Najima Y et al. Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/ SCID/IL2r gamma(null) humanized mice. Proc. Natl Acad. Sci. USA 107(29), 13022-13027 (2010).
64. Mota J, Rico-Hesse R. Humanized mice show clinical signs of dengue fever according to infecting virus genotype. J. Virol. 83(17), 8638-8645 (2009).
65. Mota J, Rico-Hesse R. Dengue virus tropism in humanized mice recapitulates human dengue fever. PLoS ONE 6(6), e20762 (2011).
66. Lan P, Tonomura N, Shimizu A, Wang S, Yang Y-G. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/ liver and CD34+ cell transplantation. Blood 108(2), 487-492 (2006).
67. Melkus MW, Estes JD, Padgett-Thomas A et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat. Med. 12(11), 1316-1322 (2006).
68. Biswas S, Chang H, Sarkis PTN, Fikrig E, Zhu Q, Marasco WA. Humoral immune responses in humanized BLT mice immunized with West Nile virus and HIV-1 envelope proteins are largely mediated via human CD5+ B cells. Immunology 134(4), 419-433 (2011).
69. Stoddart CA, Maidji E, Galkina SA et al. Superior human leukocyte reconstitution and susceptibility to vaginal HIV transmission in humanized NOD-scid IL-2R (-/-) (NSG) BLT mice. Virology 417(1), 154-160 (2011).
70. Cox J, Mota J, Sukupolvi-Petty S, Diamond MS, Rico-Hesse R. Mosquito bite delivery of dengue virus enhances immunogenicity and pathogenesis in humanized mice. J. Virol. 86(14), 7637-7649 (2012).
71. Jaiswal S, Pazoles P, Woda M et al. Enhanced humoral and HLA-A2-restricted dengue virus-specific T-cell responses in humanized BLT NSG mice. Immunology 136(3), 334-343 (2012).
72. Traggiai E, Chicha L, Mazzucchelli L et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304(5667), 104-107 (2004).
73. Kuruvilla JG, Troyer RM, Devi S, Akkina R. Dengue virus infection and immune response in humanized RAG2(-/-)gamma(c)(-/-) (RAG-hu) mice. Virology 369(1), 143-152 (2007).
74. Frias-Staheli N, Dorner M, Marukian S et al. Utility of humanized BLT mice for analysis of dengue virus infection and antiviral drug testing. J. Virol. 88(4), 2205-2218 (2014).
75. Zompi S, Harris E. Animal models of dengue virus infection. Viruses 4(1), 62-82 (2012).
76. Weiskopf D, Yauch LE, Angelo MA et al. Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design. J. Immunol. 187(8), 4268-4279 (2011).
77. Atrasheuskaya A, Petzelbauer P, Fredeking TM, Ignatyev G. Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol. Med. Microbiol. 35(1), 33-42 (2003).
78. Rajmane Y, Shaikh S, Basha K et al. Infant mouse brain passaged Dengue serotype 2 virus induces non-neurological disease with inflammatory spleen collapse in AG129 mice after splenic adaptation. Virus Res. 173(2), 386-397 (2013).
79. Amorim JH, Pereira Bizerra RS, dos Santos Alves RP et al. A genetic and pathologic study of a DENV2 clinical isolate capable of inducing encephalitis and hematological disturbances in immunocompetent mice. PLoS ONE 7(9), e44984 (2012).
80. Avirutnan P, Fuchs A, Hauhart RE et al. Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J. Exp. Med. 207(4), 793-806 (2010).
81. Morrison J, Laurent-Rolle M, Maestre AM et al. Dengue virus co-opts UBR4 to degrade STAT2 and antagonize type I interferon signaling. PLoS Pathog. 9(3), e1003265 (2013).
82. Tuiskunen A, Wahlström M, Bergström J, Buchy P, Leparc-Goffart I, Lundkvist A. Phenotypic characterization of patient dengue virus isolates in BALB/c mice differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome. Virol. J. 8, 398 (2011).
83. Ferreira GP, Figueiredo LB, Coelho LFL et al. Dengue virus 3 clinical isolates show different patterns of virulence in experimental mice infection. Microbes Infect. 12(7), 546-554 (2010).
84. Binh PT, Matheus S, Huong VTQ, Deparis X, Marechal V. Early clinical and biological features of severe clinical manifestations of dengue in Vietnamese adults. J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol. 45(4), 276-280 (2009).
85. Tanner L, Schreiber M, Low JGH et al. Decision tree algorithms predict the diagnosis and outcome of dengue fever in the early phase of illness. PLoS Negl. Trop. Dis. 2(3), e196 (2008).
86. Chiang C-Y, Huang M-H, Hsieh C-H et al. Dengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responses. PLoS Negl. Trop. Dis. 6(5), e1645 (2012).
87. Chiang C-Y, Pan C-H, Hsieh C-H et al. Lipidated dengue-2 envelope protein domain III independently stimulates long-lasting neutralizing antibodies and reduces the risk of antibody-dependent enhancement. PLoS Negl. Trop. Dis. 7(9), e2432 (2013).
88. Schlesinger JJ, Brandriss MW, Walsh EE. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J. Gen. Virol. 68(Pt 3), 853-857 (1987).
89. Qu X, Chen W, Maguire T, Austin F. Immunoreactivity and protective effects in mice of a recombinant dengue 2 Tonga virus NS1 protein produced in a baculovirus expression system. J. Gen. Virol. 74(Pt 1), 89-97 (1993).
90. Zhang YM, Hayes EP, McCarty TC et al. Immunization of mice with dengue structural proteins and nonstructural protein NS1 expressed by baculovirus recombinant induces resistance to dengue virus encephalitis. J. Virol. 62(8), 3027-3031 (1988).
91. Srivastava AK, Putnak JR, Warren RL, Hoke CH. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine 13(13), 1251-1258 (1995).
92. Wu S-F, Liao C-L, Lin Y-L et al. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine 21(25-26), 3919-3929 (2003).
93. Guirakhoo F, Arroyo J, Pugachev KV et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J. Virol. 75(16), 7290-7304 (2001).
94. Amorim JH, Diniz MO, Cariri FAMO et al. Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant. Vaccine 30(5), 837-845 (2012).
95. Azevedo AS, Yamamura AMY, Freire MS et al. DNA vaccines against dengue virus type based on truncate envelope protein or its domain III. PLoS ONE 6(7), e20528 (2011).
96. Costa SM, Yorio AP, Gonçalves AJS et al. Induction of a protective response in mice by the dengue virus NS3 protein using DNA vaccines. PLoS ONE 6(10), e25685 (2011).
97. Henriques HR, Rampazo EV, Gonçalves AJS et al. Targeting the non-structural protein 1 from dengue virus to a dendritic cell population confers protective immunity to lethal virus challenge. PLoS Negl. Trop. Dis. 7(7), e2330 (2013).
98. Kyle JL, Balsitis SJ, Zhang L, Beatty PR, Harris E. Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model. Virology 380(2), 296-303 (2008).
99. Huang CY-H, Butrapet S, Tsuchiya KR, Bhamarapravati N, Gubler DJ, Kinney RM. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J. Virol. 77(21), 11436-11447 (2003).
100. Costa SM, Azevedo AS, Paes MV, Sarges FS, Freire MS, Alves AMB. DNA vaccines against dengue virus based on the ns1 gene: the influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice. Virology 358(2), 413-423 (2007).
101. Tan GK, Ng JKW, Trasti SL, Schul W, Yip G, Alonso S. A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl. Trop. Dis. 4(4), e672 (2010).
102. Gonçalves D, de Queiroz Prado R, Almeida Xavier E et al. Imunocompetent mice model for dengue virus infection. ScientificWorldJournal 2012, 525947 (2012).